Intervention not reported
Acetazolamide + medroxyprogesterone versus medroxyprogesterone: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide + medroxyprogesterone versus medroxyprogesterone: risk… (low certainty).
1 finding from 1 review
Intervention not reported
Acetazolamide + medroxyprogesterone versus acetazolamide: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in acetazolamide + medroxyprogesterone versus acetazolamide: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Normal versus simulated altitude conditions: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in normal versus simulated altitude conditions: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Positive end‐expiratory pressure (PEEP) versus nothing: risk of AMS · participants at risk of high altitude illness
The intervention may leads to higher positive end‐expiratory pressure (PEEP) versus nothing: risk of AMS (low certainty).
1 finding from 1 review
OR 3.67 [1.38, 9.76]
1 study · 8 participants
Low
Intervention not reported
Remote ischaemic preconditioning (RIPC) versus placebo: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in remote ischaemic preconditioning (RIPC) versus placebo: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Comparisons: outcome · participants at risk of high altitude illness
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Intervention not reported
Antioxidants versus placebo: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in antioxidants versus placebo: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Ginkgo biloba versus placebo: risk of AMS · participants at risk of high altitude illness
The intervention may leads to lower ginkgo biloba versus placebo: risk of AMS (low certainty).
1 finding from 1 review
Intervention not reported
Erythropoietin versus placebo: risk of AMS · participants at risk of high altitude illness
It is very uncertain whether the intervention changes erythropoietin versus placebo: risk of AMS (very low certainty).
1 finding from 1 review
Intervention not reported
Medroxyprogesterone versus placebo: risk of AMS · participants at risk of high altitude illness
The intervention showed no clear difference in medroxyprogesterone versus placebo: risk of AMS (low certainty).
1 finding from 1 review
Benzodiazepine discontinuation, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine withdrawal symptoms, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine discontinuation, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine withdrawal symptoms, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine discontinuation, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine withdrawal symptoms, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine discontinuation, longest · adults who withdraw from chronic benzodiazepine use
Tricyclic antidepressants may leads to higher benzodiazepine discontinuation, longest compared with placebo (low certainty).
1 finding from 1 review
Benzodiazepine withdrawal symptoms, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine discontinuation, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review
Benzodiazepine withdrawal symptoms, longest · adults who withdraw from chronic benzodiazepine use
1 finding from 1 review